Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 11/20 | 0.50 |
| ▸ | ALOX5AP | P20292 | 3/20 | 0.49 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | CYSLTR1 | Q9Y271 | 2/20 | 0.43 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.43 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1423624 | 0.90 | PDE10A (0.50) | PDE10AALOX5HDAC6CYSLTR1CYSLTR2 | |
| SCHEMBL1424150 | 0.89 | PDE10A (0.49) | PDE10AALOX5APALOX5HDAC6CYSLTR1 | |
| SCHEMBL1424028 | 0.89 | PDE10A (0.55) | PDE10AALOX5HDAC6CYSLTR1CYSLTR2 | |
| SCHEMBL1423597 | 0.88 | ALOX5AP (0.45) | PDE10AALOX5APALOX5HDAC6CYSLTR1 | |
| SCHEMBL1423812 | 0.83 | PDE10A (0.46) | PDE10AALOX5APALOX5HDAC6CYSLTR1 | |
| SCHEMBL1423654 | 0.79 | PDE10A (0.51) | PDE10AALOX5APALOX5HDAC6CYSLTR1 | |
| SCHEMBL1423583 | 0.79 | PDE10A (0.51) | PDE10AALOX5HDAC6CYSLTR1CYSLTR2 | |
| SCHEMBL1423590 | 0.75 | PDE10A (0.62) | PDE10AALOX5APALOX5CYSLTR1CYSLTR2 | |
| SCHEMBL1423645 | 0.75 | PDE10A (0.54) | PDE10AALOX5APALOX5CYSLTR1CYSLTR2 | |
| SCHEMBL10549182 | 0.74 | CYSLTR1 (0.57) | PDE10AALOX5APALOX5HDAC6CYSLTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110224204-A1 | DI-SUBSTITUTED PHENYL COMPOUNDS | ENVIVO PHARMACEUTICALS, INC. | 2011-09-15 | — | — | US | disclosed |
| EP-2297131-A2 | DI-SUBSTITUTED PHENYL COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | Envivo Pharmaceuticals, Inc. (US) | 2011-03-23 | — | — | EP | disclosed |
| WO-2009158467-A2 | DI-SUBSTITUTED PHENYL COMPOUNDS | ENVIVO PHARMACEUTICALS, INC. (US) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224204-A1 | DI-SUBSTITUTED PHENYL COMPOUNDS | PDE10A, PDE1A, PDE12 | PDE10A 1/4885ALOX5AP 1764/4885ALOX5 1734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.